FDA Approved: XELJANZ — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)

View source ↗

Summary

The FDA approved a supplemental application for XELJANZ (tofacitinib) filed by Pfizer Laboratories Div Pfizer Inc, resulting in changes to the drug’s labeling o…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Juvenile Idiopathic Arthritis
• Plaque Psoriasis
• Psoriatic Arthritis
• Rheumatoid Arthritis
• Ulcerative Colitis

Drugs mentioned

• XELJANZ (tofacitinib)

Snippet

SUPPL AP for XELJANZ (TOFACITINIB)